This study has summarized the development of Docetaxel (DOC) loaded nanocapsules (NCs) intended for breast cancer (BC) therapy. These NCs are composed of a lipid core to encapsulate the hydrophobic DOC and a polymeric shell for surface functionalization. DOC was efficiently encapsulated within the oily core of NCs. The critical role of stabilizers on NCs stealthiness and anticancer drug efficacy was investigated. The potential impact of surface chemistry on the cytotoxicity and phagocytic clearance of NCs for a subsequent improvement of the efficacy of DOC in BC treatment was explored. The in vitro cell culture studies in cancer cell lines showed a significant enhancement of the cytotoxicity of DOC due to its high loading within the NCs. Interestingly, the NCs were stable during storage and could be efficiently transformed into powder form using freeze-drying method. It is also hypothesized that DOC-loaded hyaluronic acid (HA) grafted oily core NCs can enhance the drug cytotoxicity and uptake in CD44 expressing BC cells (MDA-MB 231). These novel nanostructures hold the promise to support the potential clinical application and cost-effectiveness of innovative nanotherapeutics in cancer therapy.
Introduction
Cancer has been estimated to cause more than 8.2 million deaths, counted with approximately 14.1 million new cases in 2012 and representing one of the leading causes of death worldwide [1] . The two major challenges in the field of cancer drug delivery include selective drug targeting to the diseased tissues and reduced side effects. In cancer therapy, most of the proposed formulations present certain drawbacks related to the low drug loading, dose-dependent toxicity, and unsuitable release pattern. Conventional chemotherapy usually provides modest tumor response and generates undesirable side effects due to the nonspecific action of drugs [2] . The use of nanoscale drug delivery vehicles represents a promising strategy for improving the intracellular delivery of anticancer drug molecules and to reduce the associated dose related toxic side effects [3] . An ideal formulation for cancer therapy should provide biocompatible nano-sized vehicles, efficiency to the target cells, and high drug loading with sustained-release characteristics. This allows releasing the drug at the target site in its therapeutic concentration and preventing drug inefficiency and side effects. However, these nano-sized delivery systems suffer from easy recognition by the reticuloendothelial system (RES) and consequently, rapid elimination by the liver and spleen [4] . This is due to the fact that, after intravenous administration, the in vivo fate of a delivery system is significantly influenced by interactions REVIEW between carrier and plasma/serum proteins, resulting in the adsorption of opsonin proteins present in the blood serum on the nanocarrier surface [5] . These opsonized carriers can be easily recognized and cleared from the blood circulation by the mononuclear phagocytic system (MPS) before the accomplishment of their designated therapeutic functions [5] . In addition, the intracellular localization of most anticancer agents requires the development of ligand targeted nanocarriers capable of being actively internalized by cancer cells, and ultimately releases the therapeutic agent in the cytoplasm of malignant cells. Therefore, there is an imperative need for developing a targeted nano-sized delivery system with reduced phagocytic clearance capable of efficiently and safely deliver therapeutic agents to the targeted tumor tissues. In this regard, pegylation (surface modification with polyethylene glycol: PEG) has been proven as one of the promising approaches to improve the in vivo circulation as well as the intracellular concentration of drugs in the tumor cells [6, 7] .
Breast cancer (BC) is one of the most common malignant tumors and one of the first causes of morbidity and mortality among women worldwide [8] . The lack of specific biomarkers is one of the major limitations for the effective diagnosis and therapy of BC. Therefore, the formulation of nanocarriers bearing efficient and active target molecules becomes challenging for the development of novel BC therapies [9] [10] . Different strategies have been proposed as possible approaches for an active targeting in BC. These include peptides, biodegradable polymers, antibodies, aptamers, siRNA, and aptamer-siRNA chimera [11] [12] [13] [14] .
Docetaxel (DOC) has been shown to be a highly potent anticancer agent against various types of cancer, including BC, non-small cell lung cancer, ovarian cancer, leukemia, and prostate cancer [15, 16] . DOC is an active cytotoxic agent that promotes the polymerization of tubulin and the stabilization of microtubules by preventing their disassembly. However, DOC is associated with numerous drug-related toxicities due to the high doses used to achieve the desired effect and its non-specific distribution [17] . Taken together, substantial efforts are needed to develop a novel, less toxic and effective formulations of DOC in the tumor site.
In recent years, the nanocapsule (NC) delivery systems have been considered as a potential means to deliver the drug to the target site with specificity, if modified, and to maintain the desired concentration at the site of interest without unwanted effects [18] [19] [20] . NCs as vesicular systems can have a liquid core capable to encapsulate lipophilic or hydrophilic drug molecules and surrounded by a polymeric shell. This specific structure makes them quite versatile. Their lipid core allows the efficient encapsulation of lipophilic drugs (most anticancer drugs are lipophilic), whereas their polymeric shell may have the role of improving the stability of the oily droplets and facilitating their uptake by the cancer cells. Moreover, the presence of the polymer around the oily core offers the possibility of chemical modifications, which may further improve the stability, cellular uptake and biodistribution of NCs [15, [21] [22] .
Within this frame, the main objective of this review is to summarize the recent work done by the authors towards the development of various types of NCs and to evaluate their potential for the intracellular delivery of DOC. These polymeric NCs display a number of properties, among which it is important to highlight: (i) their capacity to be internalized by different cell lines, such as the MCF-7 cell lines (ii) the improved efficacy of DOC-loaded NCs compared to native DOC in MCF-7 cell lines; and (iii) the possibility to functionalize them with various ligands in order to target the receptors that are specifically overexpressed in cancer cells. In addition, the influence of NCs surface coating composition, stabilizer concentration, stabilizer type as well as the oil amount on the physicochemical properties of the NCs was also evaluated.
The first type of NCs was prepared by using polyester intended for BC therapy [21] . Polysorbate 80 has been markedly used to improve the aqueous solubility of DOC [23] . However, this currently available marketed formulation has been associated with the non-selectivity for target tissues, major dose limiting toxicities, hypersensitivity reactions, as well as sensory and motor neuropathies that are sometimes severe and irreversible [21] . Therefore, the development of compatible polymer-based nanocarriers with high drug loading might be a helpful subject in BC therapy. Considering this, we hypothesized that DOC containing oily core NCs can be successfully prepared with a high drug encapsulation efficiency (EE %) and loading (DL %) using emulsion-diffusion method [21] . The design of experiment approach has been applied to synthesize the oily core NCs since it has been extensively used these days in nano-formulation and analytical research areas [24] [25] [26] . The oily core NCs were generated using neutral Labrafac CC and poly (d,l-lactide) [PLA] as oily core and shell materials, respectively. Four polymers were initially screened including PLA R206, PLA R207, PLA R208, and polycaprolactone (PCL) to find out their effects on developing small-sized NCs. In addition, the effect of different molecular weights (MW: 9 to 10 kDa and 30 to 70 kDa) of polyvinyl alcohol (PVA) was further analyzed. Results indicated that a statistically significant decrease in the diameters of the PLA based NCs' was observed with increasing polymer molecular weights. Based on their smaller particle mean diameter (PMD: 110.8 ± 8.6 nm, n=3), NCs prepared with PLA R208 and PVA MW: 30-70 kDa were selected for the subsequent studies [21] . Interestingly, the driven force for the drug encapsulation was found to be the hydrophobicity of the formulation components (DOC, PLA and Oil). To our knowledge, only a few examples in the literature deal with describing the effect of the drug state on its release kinetic from nanocarriers. Indeed, a significant change in the crystallinity of the polymer and the native drug may affect the drug release rate and subsequently its release kinetics [27] . Powdered X-ray Diffraction (PXRD) analysis revealed that DOC became amorphous and was likely to be dissolved within the NCs' oily core and probably in the PLA shell. The incorporated crystalline drug was deposited on the surface of the NCs, thus triggering the burst release of the drug, while the drug was molecularly dispersed in its amorphous state in the oily core and polymer and released in a controlled manner. Accordingly, the in vitro release of DOC was supported by Higuchi's release kinetic model, i.e., based on Fickian diffusion [21] . The drug compatibility with the polymer solution was also shown to be an important factor that contribute in the drug encapsulation efficiency and controlled release profile of the drug. For this purpose, we aimed to predict the compatibility and interaction parameter (Χsp) between DOC (solubilizate) and polymer (solvent) using the thermodynamic approach based on the extended Hildebrand solubility followed by the Flory-Huggins solubility parameter [28] .
The in vitro cytotoxicity of DOC and DOC-loaded NCs at different equivalent drug concentrations (1 nM, 2.5 μM, and 5 μM) was evaluated on SUM 225 cells using lactate dehydrogenase (LDH) assay. Cytotoxicity studies revealed that at the highest drug concentration (5 μM), the DOC-loaded oily core NCs enhanced the native drug cytotoxicity. However, at lower concentrations, the native DOC appeared to be more bioactive, probably due to the rapid diffusion and higher drug cellular uptake. It was also observed that at high concentration of drug-loaded NCs' the cytotoxicity was significantly enhanced compared to that of the native DOC. This might be due to the NCs uptake by SUM 225 cells and sustained drug release profile from the NCs. These results clearly suggested that the oily core NC formulation (as a reservoir system for the drug) could enhance the biological responses of the native DOC at higher drug payload. To further investigate the NCs cellular uptake on BC cells, we hypothesized that the NC surface chemistry might play a critical role in the cell-NCs interaction. This leads to explain our next work, where we analyzed the effect of surface chemistry of the NCs on cytotoxicity and cellular uptake [15] .
Research has currently been shifted towards the optimization of the nanocarrier surface chemistry for improved cancer diagnosis and therapy [29, 30] . Besides the nanocarrier's size and shape, the surface chemistry may play a critical role in the carrier-cell interactions [31] . In that respect, effort was devoted to understand the mechanism underlying the NC endocytic pathways and its toxicity in BC and phagocytic cells [15] . Despite the number of scientific publications dedicated to the use of drug-loaded nanocarriers in cancer research, the number of nano delivery systems approved by the US Food and Drug Administration (FDA) is still limited. These limitations have been attributed to the toxicity, physicochemical instability, environmental impact and extensive uptake of nanocarriers by the MPS system [32] .
To improve our understanding of carrier-cell interactions, NCs with well-characterized surface chemistry/composition were engineered and tested in vitro. The study was focused on the preparation and optimization of DOC-loaded NCs stabilized with tween 80 (NCT80) using the Box-Behnken experimental design [15] . The physicochemical characterization of the newly synthesized NCT80 in comparison with our previously engineered oily core NCs stabilized with PVA (NCPVA) was performed. Preliminary results indicated that the synthesized NCs have almost similar size (PMD: 123.02 ± 14.60 nm for NCT80; and 110.8 ± 8.6 nm for NCPVA, n=3) and zeta potential values (ζ average: -36.5 ± 9 mV for NCT80; and -35.9 ± 3.7 mV for NCPVA, n=3). The high absolute values of zeta potential may have contributed to improve the stability of nanocarriers by increasing the repulsive potential of adjacent particles [33] .
Here, the surface composition was the only difference between these two types of NCs (NCT80 and NCPVA). As shown by the X-Ray photoelectron spectroscopy (XPS), Tween 80 and PVA molecules were still present on the surface of their respective NCs after their synthesis and three-step washing. In vitro drug release data from NCT80 formulations provided a better fit to zero order kinetic models, indicating that the drug release rate was independent of its concentration. Interestingly, the drug release from NCPVA formulations was consistent with the Higuchi kinetic model, where the percentage of the drug released was plotted versus the square root of time. In this case, the polymer erosion might have been occurred after slow hydrolytic degradation of PLA monomers [34] . However, little information regarding the potential effect of stabilizer on nanocarriers is available. Therefore, we have investigated their cytotoxic effect, and phagocytic pathways in BC cells. The results exhibit minor toxicity of both types of blank NCs, thus attributing the further cytotoxicity to the formulated drug. Despite the negative surface charge of the cell membrane and NCs, no detectable electrostatic repulsion between cells and NCs was noticed. This was also supported by the increased uptake of both types of NCs in a concentration and energy dependent manner in MDA-MB 231 cells, THP-1 monocytes and THP-1 derived macrophages [15] . Attention must be taken on the selected pharmacological inhibitors regarding their intrinsic toxicity and fluorescence interference while performing particle cellular uptake studies [35] . These inhibitors are cytochalasin D, chlorpromazine, genistein, phorbol myristate acetate, dynasore, latrunculin A and sodium azide. For this purpose, cells viability assay was performed using MDA-MB 231 cells, THP-1 monocytes, and its derived macrophages. As indicated, cells treated with the above inhibitors (at their respective working concentrations) showed no toxic effect. On the other hand, their suspected intrinsic toxicity was not detected. Furthermore, the functionality of different endocytic pathways was thoroughly investigated using positive controls to avoid false positive experimental results. These positive controls included transferrin (Tf), cholera toxin B (CT-B), FITC-albumin (ALb), low-density lipoprotein (LDL), and latex beads (Ø: 2.4 μm) for clathrin, caveolae, cytoskeleton, macropinocytosis, and phagocytosis-mediated endocytic pathways, respectively [15] . Overall, our results indicated a reduced phagocytic clearance of NCT80 compared to NCPVA. In addition, the uptake of NCPVA in MDA-MB 231 cells revealed a multifacetic pattern in MDA-MB 231 cells. In macrophages, uptake of NCT80 was occurred through a monofacetic pattern via phagocytosis, while the NCPVA were taken up through a multifacetic pattern. These findings indicated the importance of surface composition of the nanocarriers in the biological fate. To further investigate the cellular uptake and cytotoxicity of such nanocarriers, hyaluronic acid (HA) functionalized NCs were synthesized and challenged with BC cells (Figure 1 ) as indicated [22] .
HA is a glycosaminoglycan that offers the possibility of targeting, and promotes the intracellular access of the drug-loaded nanocarriers to the cancer cells that overexpress the endogenous CD44 receptors [36] [37] via specific endocytic pathway(s) [38] [39] . In BC cells, the influence of HA on cell migration has been clinically shown to be CD44 dependent [40] . In addition, pathological conditions have been correlated with the enhancement of HA binding to CD44 that lead to increased tumor progression [41] . Therefore, the use of HA as a ligand to actively target advanced CD44 positive BC could be a promising approach. Moreover, HA presents interesting physicochemical properties including high water-solubility, biocompatibility, biodegradability, non-immunogenicity, and chemical structure suitable for further functionalization [39] . All together make HA an attractive biomaterial to be applied concomitantly as a targeting and stabilizing moiety in the development of cancer-targeting and other drug delivery systems for various applications [36, [42] [43] [44] .
Taking this background information, we have synthesized a surfactant-free HA based NCs with high drug (DOC) payload [23] . Pharmaceutical parameters such as drug release, stability during storage and reconstitution of freeze-dried HA functionalized NCs render them extremely challenging as novel platforms for the intracellular delivery of anticancer drugs. The physicochemical characteristics and the effect of the freeze-drying on the NCs mean diameter were also analyzed. HA-conjugated PEG/poly (ε-caprolactone, PEG/PCL) was used to synthesize DOC-loaded HA-PEG/PCL-grafted NCs. The hydrophilic nature of PEG combined with HA represents the hydrophilic moiety of the conjugate. Ligand (HA) attachment to PEG on the surface of such small-sized NCs (<200 nm) concomitantly allowed prolonging the NCs systemic circulation time, and enhanced the permeability and retention (EPR) effect [45] . In addition to the PCL moiety, the hydrophobic oily core of the synthesized NCs allowed a higher encapsulation of hydrophobic drug (DOC) through hydrophobic interactions [21] .
In vitro cytotoxicity of the synthesized NCs was investigated to test the potential toxicity of DOC-loaded HA-PEG/PCL-grafted NCs in cancer cells [23] . For the cellular uptake study, the NCs were fluorescently labeled with fluorescein isothiocyate (FITC) to quantify and monitor their internalization in MDA-MB 231 cells. Furthermore, the involvement of CD44 receptors in the NC cellular internalization was tested using an anti-CD44 antibody and a CD44-negative NIH3T3 cell lines as positive and negative control, respectively. After encapsulation of DOC in the oily core of the NCs, a partial amorphization of DOC reducing its crystallinity was observed which was consistent with our previous work [15] . The drug release profile exhibited a tri-phasic release pattern which might be due to the high molecular weight associated with the marked hydrophobicity of PCL in the oily core of the NCs. The tri-phasic drug release behavior from such nanocarriers has been described elsewhere [46, 47] . Most of the tested formulations fitted with the first order equation, indicating the drug concentration-dependence on the release of DOC from NCs.
A paradoxal effect of HA in eliminating malignant cells while contributing in the detoxification of oxidative agents, such as reactive oxygen species (ROS), that might synergistically enhanced the toxicity against malignant cells was noticed. In addition to the ROS-scavenging property of HA at high concentration of DOC-HA-PEG/PCL-grafted NCs, an increase in the intracellular concentrations of reduced glutathione (GSH) compared to that of DOC-loaded PEG NCs was evidenced. The effect of HA on the intracellular level of GSH could be cell dependent. The in vitro cytotoxicity results including mitochondria damage, ROS, and GSH, contributed to understand the mechanism of the toxicity of DOC-loaded HA-PEG/PCL NCs in MDA-MB 231 cells. On the other hand, cellular internalization results consistently showed a significant enhancement of the uptake of HA-PEG/PCL-grafted NCs (up to 4 folds) in comparison with PEGylated NCs [23] . These findings are consistently correlated with the high toxicity of DOC-loaded HA-PEG/PCL-grafted NCs analyzed by using cell viability (MTS) assay. A reasonable explanation is that the presence of HA on the surface of the NCs may contributed to enhance the cellular uptake efficacy through the high binding affinity of HA towards the extracellular domain of the CD44 receptors in MDA-MB 231 cells. Conversely, a decreased particle cellular uptake was observed after pretreatment with an anti-CD44 antibody at medium and high concentrations of HA-PEG/PCL-grafted NCs compared to that of PEG NCs, thus supporting the above statement. So far, the mechanism of HA binding to the CD44 is still not understood. As a consequence of these properties, HA-based nanocarriers have been resulted in an improved cancer cell growth inhibition in vitro, compared to the native drug. These results showed that HA-PEG/PCL-grafted NCs could be a promising template for cancer therapy.
Conclusions and perspectives
The results explained here indicated that DOC-loaded oily core NCs showed high drug loading. The miscibility of DOC in the hydrophobic oily core of the NCs appeared to be the main factor governing its high entrapment. The presence of surfactant on the surface of NCs plays a critical role in the cellular uptake and cytotoxicity of the NCs and subsequently on its biological fate. More interestingly, the presence of HA on the surface of the NCs is a great progress for a target delivery of DOC towards CD44 positive BC cell. This new prototype of NCs exhibited a capacity to enter the tumors cells and deliver the associated drug intracellularly, thus resulting in an excellent vehicle for further studies. Future work is dedicated to analyze the in vivo biodistribution, safety and efficacy studies of HA-PEG/ PCL-grafted NCs in mice bearing tumor will make great strides in advancing targeted cancer therapy. Although, there are no FDA-approved DOC-loaded nanocarrier-bearing HA based anticancer drug formulations on the market, accumulated information reported here evidences the potential of these nanocarriers. The versatility of PEGylated HA-decorated NCs can be a unique template for ligand labeled with positron emitting carbon using positron emission tomography (PET) imaging for cancer diagnosis, therapy and prognosis.
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